NCI-60
cell line panel
The NCI-60 cancer cell line panel is a group of 60 human cancer cell lines used by the National Cancer Institute (NCI) for the screening of compounds to detect potential anticancer activity.
Purpose
The screening procedure is called the NCI-60 Human Tumor Cell Lines Screen, and it is one of the Discovery & Development Services of NCI's Developmental Therapeutics Program (DTP).
The screening rates for each cell line the cytostatic and cytotoxic impact of tested substances.
Due to the diversity of the cell lines, it is possible to compare tested compounds by their effect patterns, high correlation potentially corresponding to similar effect mechanisms.
An automated comparison against a database of more than 88,000 pure compounds and more than 34,000 crude extracts (as of 6 January 2017) is provided by the COMPARE tool, which shows a list of substances ranked by the Pearson correlation coefficients for a given test substance.
The same panel is used in the Molecular Target Program for the characterization of molecular targets. Measurements include protein levels, RNA measurements, mutation status and enzyme activity levels.
Cell Lines
The panel holds cell lines representing leukemia, melanoma, non-small-cell lung carcinoma, and cancers of the brain, ovary, breast, colon, kidney, and prostate.
13 additional cell lines are evaluated for use in the screening program,
among them two lines deriving from so far not represented small-cell lung carcinoma.
All cell lines but one (as of 6 January 2017) are available to other laboratories, including the additional cell lines.
This brief starts where responsible research should: with the source description of “NCI-60” as cell line panel. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the general reference register because the source frames it as cell line panel. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Dec 6, 2025. The linked authority identifier is Q49000430. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2017.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “NCI-60”, its source revision and the description used here.
- Expand the search: follow NCI-60 primary sources, NCI-60 archive and NCI-60 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “NCI-60”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “NCI-60” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.